Utomilumab - Pfizer

Drug Profile

Utomilumab - Pfizer

Alternative Names: 4-1BB agonist monoclonal antibody- Pfizer; PF-05082566; PF-2566; PF-5082566

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer M. D. Anderson Cancer Center; National Cancer Institute (USA); Pfizer; Stanford University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Oropharyngeal cancer; Solid tumours
  • Phase I Breast cancer; Colorectal cancer
  • No development reported B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 04 Apr 2018 Phase-II clinical trials in Oropharyngeal cancer (Combination therapy, Second-line therapy or greater, First line therapy) in USA (IV) (NCT03258008)
  • 30 Jan 2018 Pfizer plans the phase II AVIATOR trial for Breast Cancer in the US , (NCT03414658)
  • 18 Jan 2018 Kite Pharma and Pfizer agree to co-develop utomilumab, in combination with axicabtagene ciloleucel, for B-cell lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top